US EditionNeurizon Enters Into Global License with Elanco to Accelerate Commercialisation of NUZ-001
- Neurizon signed a significant license agreement with Elanco to advance the commercialization of NUZ-001.
- This agreement strengthens Neurizon's strategic outlook for the development and commercialization of NUZ-001.
- The deal provides exclusive access to important non-clinical studies and manufacturing data, helping to reduce costs and speed up development.
- Neurizon and Elanco aim to finalize a supply agreement later in 2025, with an announcement expected in H2 CY 2025.
56 Articles
56 Articles
The Australian
The MercuryNeurizon enters global licensing deal
Neurizon significantly advances NUZ-001, enters global licensing agreement
Neurizon Therapeutics (ASX:NUZ) has this week arrived at its next “watershed moment” as it looks to become a leader in neurodegenerative disease treatments, executing a global license agreement with Elanco Animal Health Inc. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. The deal will see Elanco and its affiliates share Monepantel, the acti…
Neurizon inks global licensing deal with NYSE-listed Elanco
Neurizon enters global licensing deal with Elanco for monepantel, the key ingredient of its lead drug candidate NUZ-001 Deal grants Neurizon exclusive global rights to utilise Elanco’s IP, including access to non-clinical studies, and manufacturing data Provides key terms for future supply agreement for GMP-compliant monepantel and pathway for accelerated commercialisation of NUZ-001 Special Report: Neurizon Therapeutics has inked an exclusi…
Coverage Details
Bias Distribution
- 66% of the sources are Center
To view factuality data please Upgrade to Premium
